Press Releases May 21, 2026 04:05 PM

PacBio to Participate in the Jefferies Global Healthcare Conference

PacBio to Present at Jefferies Global Healthcare Conference to Showcase Sequencing Innovations

By Sofia Navarro PACB

Pacific Biosciences (PacBio), a leader in high-quality DNA sequencing technology, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026. The event will provide insights into their advanced sequencing solutions and future prospects. A live webcast and replay will be available to investors and interested parties.

PacBio to Participate in the Jefferies Global Healthcare Conference
PACB

Key Points

  • PacBio management will participate in Jefferies' Global Healthcare Conference, enhancing investor engagement.
  • The company focuses on HiFi long-read sequencing technology applicable across human genomics, plant and animal sciences, infectious disease, and oncology research sectors.
  • Live webcast and replay access improve transparency and accessibility for investors and stakeholders.

MENLO PARK, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Jefferies’ Global Healthcare Conference on Thursday, June 4, 2026, at 2:00 PM ET in New York, New York.

A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the event.

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Contacts

Investors:
[email protected]

Media:
[email protected]


Risks

  • The products are for Research Use Only and are not approved for diagnostic procedures, which may limit revenue expansion in clinical markets.
  • Market adoption of advanced sequencing technologies is competitive and dependent on continued technological innovation.
  • Dependency on ongoing research funding and collaborations could impact growth amid shifting healthcare budgets.

More from Press Releases

LiqTech International Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Jun 4, 2026 Correction: Keystone Acquisition Corp. Announces Closing of $287.5 Million Initial Public Offering Including Exercise of Underwriters’ Over-Allotment Option Jun 4, 2026 Verizon declares quarterly dividend on June 4, 2026 Jun 4, 2026 AmperCap Acquisition Company Completes its $125,000,000 Initial Public Offering Jun 4, 2026 Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026